

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
26 January 2006 (26.01.2006)

PCT

(10) International Publication Number  
**WO 2006/008160 A1**

(51) International Patent Classification<sup>7</sup>: C07D 277/20,  
A61K 31/425

(21) International Application Number:  
PCT/EP2005/007958

(22) International Filing Date: 21 July 2005 (21.07.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0416379.6 22 July 2004 (22.07.2004) GB

(71) Applicant (for all designated States except US): SANDOZ  
AG [CH/CH]; Lichstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KREMMINGER,  
Peter [AT/AT]; Klammstrasse 17B, 6330 Kufstein (AT).  
SILBERBERGER, Herbert [AT/AT]; Niederachen 47,  
6311 Oberau-Wildschönau (AT).

(74) Agent: DIETZ, Jörg; Novartis AG, Corporate Intellectual  
Property, CH-4002 Basel (CH).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KM, KP, KR, KZ, L.C., L.K., L.R., L.S., L.T., LU, LV, MA,  
MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ,  
OM, PG, PH, PI, PT, RO, RU, SC, SD, SE, SG, SK, SI,  
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,  
VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,  
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TERTIARY AMINE SALTS OF 2-(2-AMINOTHIAZOLE-4-YL)-2-ACYLOXYIMINO)ACETIC ACID

WO 2006/008160 A1



(57) Abstract: Subject of the present invention are crystalline tertiary amine salts of 2-(2-aminothiazole-4-yl)-2-(acyloxyimino)acetic acid compounds of formula (I) wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> independently represents unsubstituted or substituted alkyl, cycloalkyl or aryl, and R<sub>4</sub> denotes acyl, which may be obtained in anhydrous form. Crystalline compounds of formula I are useful in a reaction step with an activating agent in order to produce cefdinir. Additionally, a process to prepare compounds of formula I is a part of the present invention.

## TERTIARY AMINE SALTS OF 2-(2-AMINOTHIAZOLE-4-YL)-2-(ACYLOXYIMINO)ACETIC ACID

The present invention relates to tertiary amine salts of 2-(2-aminothiazole-4-yl)-2-(acyloxyimino)acetic acid in crystalline form and a process for their preparation as well as a process for the preparation of cefdinir wherein such tertiary amine salts are used.

5

It is known e.g. from ES 2 013 828 that a 2-(2-aminothiazole-4-yl)-2-(acyloxyimino)acetic acid compounds, e.g. syn-2-(2-aminothiazol-4-yl)-2-(acetoxymino)-acetic acid and its derivatives, may be used as an intermediate compound in the production of cefdinir, which is (6*R*,7*R*)-7-[[[(2*Z*)-(2-Amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-

- 10 azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid. Usually, a process for the production of cefdinir includes a reaction step wherein a 2-(2-aminothiazole-4-yl)-2-(acyloxyimino)acetic acid compound is converted into an activated form thereof such as a mercaptobenzothiazoleester, a mixed acid anhydride, an acid halide or another conventional activated form by a reaction with an activating agent. Any crystal water of 2-(2-
- 15 aminothiazole-4-yl)-2-(acyloxyimino)acetic acid also reacts with the activating agent and typically causes decreased yields in the activation step or/and the necessity of significantly increased amounts of activating agent, e.g. halogenation agent such as phosphorous pentachloride (see ES 2 013 828). Therefore, it is highly desirable to use anhydrous derivatives of a 2-(2-aminothiazole-4-yl)-2-(acyloxyimino)acetic acid compound for an
- 20 activation reaction.

However, 2-(2-aminothiazole-4-yl)-2-(acyloxyimino)acetic acid compounds, for instance syn-2-(2-aminothiazol-4-yl)-2-(acetoxymino)-acetic acid, are typically prepared from e.g. syn-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)-acetic acid by reaction with alkanoic carboxylic acid anhydrides such as acetic acid anhydride under aqueous conditions and are crystallised in a

25 hydrated form, e.g. as mono- or dihydrates. Thus, there is a need for anhydrous derivatives of 2-(2-aminothiazole-4-yl)-2-(acyloxyimino)acetic acid compounds.


The present invention is intended to provide novel crystalline tertiary amine salts of 2-(2-aminothiazole-4-yl)-2-(acyloxyimino)acetic acid compounds which are useful in a reaction

30 step with an activating agent in order to produce cefdinir. It has surprisingly been found now that crystalline tertiary amine salts of 2-(2-aminothiazole-4-yl)-2-(acyloxyimino)acetic acid compounds may be obtained in an anhydrous form.

In one aspect the present invention relates therefore to tertiary amine salts of 2-(2-

35 aminothiazole-4-yl)-2-(acyloxyimino)acetic acid compounds of formula

- 2 -




- in crystalline form, preferably in anhydrous form, wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> independently  
 5 represents unsubstituted or substituted alkyl, cyclo-alkyl or aryl, and R<sub>4</sub> denotes acyl.

In the meaning of R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> alkyl includes (C<sub>1-12</sub>)alkyl such as (C<sub>1-8</sub>)alkyl, in particular (C<sub>1-4</sub>)alkyl, e.g. ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl or tert-butyl. Aryl includes (C<sub>6-12</sub>)aryl, e.g. phenyl or naphtyl, in particular phenyl. Cycloalkyl includes (C<sub>3-6</sub>)cycloalkyl,  
 10 preferably C<sub>3</sub>, C<sub>5</sub> or C<sub>6</sub>-cycloalkyl such as cyclohexyl.

Any alkyl, cycloalkyl or aryl group of R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> may be unsubstituted or one to three times substituted, e.g. one times substituted by halogen or alkyl. Aryl and cycloalkyl may be also one to five times substituted by alkyl, e.g. (C<sub>1-4</sub>)alkyl or halogen.  
 15 In preferred embodiments of the invention R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> each denote n-butyl, ethyl, phenyl or n-octyl. In another preferred embodiment R<sub>1</sub> and R<sub>2</sub> denote iso-propyl and R<sub>3</sub> denotes ethyl. Particularly preferred are compounds wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> each denote n-butyl. R<sub>4</sub> denotes acyl such as (C<sub>1-6</sub>)acyl, e.g. formyl, acetyl, propanoyl or butanoyl. In a preferred embodiment R<sub>4</sub> denotes C<sub>2</sub>-acyl, i.e. acetyl.  
 20 If not otherwise stated herein, acyl includes (C<sub>1-8</sub>)acyl, e.g. formyl, acetyl, propanoyl or butanoyl, preferably acetyl.

An anhydrous form of a crystalline tertiary amine salt of formula I may contain less than  
 25 1.0% (w/w) of water, i.e. from about 0% to below 1.0% (w/w), e.g. from about 0.01% to about 0.5% (w/w) such as from about 0.05% to about 0.2% (w/w) or even less than about 0.1% (w/w).

Crystalline tertiary amine salts of formula I, e.g. in an anhydrous form, may be produced by  
 30 contacting 2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)-acetic acid dissolved or suspended in a solvent with an amine of formula



- wherein  $\text{R}_1$ ,  $\text{R}_2$  and  $\text{R}_3$  are defined as in formula I. For instance a hydrate of 2-(2-aminothiazol-4-yl)-2-(acyloxyimino)-acetic acid, e.g. a monohydrate, a dihydrate or a mixture thereof, is dissolved or suspended in a solvent with an amine of formula II. Crystallisation of a tertiary amine salt of formula I may occur upon stirring the solution or suspension. If desired, measures to initiate crystallization as known in the art such as cooling, adding a counter-solvent, partly evaporation of solvent or friction of a glass stick on the surface of a glass vessel may be applied in order to accelerate and complete crystallization.
- 10 The amount of added amine of formula II is not critical. An equimolar amount of a 2-(2-aminothiazol-4-yl)-2-(acyloxyimino)-acetic acid compound dissolved or suspended in a solvent and of the amine of formula II may be used, whereby a slight molar excess of the amine of formula II, e.g. around 1.01 to around 1.50 molar equivalents of an amine of formula II per equivalent of 2-(2-aminothiazol-4-yl)-2-(acyloxyimino)-acetic acid compound may be of advantage. A higher excess, for example about 1.5 to about 5 molar equivalents of an amine of formula II per equivalent of the 2-(2-aminothiazol-4-yl)-2-(acylcarbonyloxyimino)-acetic acid compound may also be used.
- 15 The reaction temperature is not critical for the crystallization of a tertiary amine salt of formula I. Suitable reaction temperatures are from -30°C to 70°C, e.g. -20°C to 35°C, particularly from -10°C to 25°C such as at ambient room temperature. Preferably, a salt of formula I is crystallized under mild temperature conditions such as at or below ambient room temperature because that would result in a very mild and gentle dehydration process leading
- 20 to high yields and very high purities of the cefdinir to be prepared from a tertiary amine salt of formula I.

Suitable solvents for the crystallisation of a tertiary amine salt of formula I, e.g. in an anhydrous form, are solvents which may typically be used for crystallisation of amine salts of beta-lactam compounds. Suitable solvents may include ketones, e.g. ( $\text{C}_{3-6}$ )-ketones, nitriles, such as ( $\text{C}_{1-8}$ )-nitriles, ethers, for example ( $\text{C}_{2-8}$ )-alkyl( $\text{C}_{2-8}$ )-alkylethers or tetrahydrofuran (THF), amides such as dimethylacetamide or dimethylformamide and chlorinated hydrocarbons such as methylenechloride and mixtures of two or more of said solvents. Preferred solvents are acetone, THF and N,N-dimethylformamide.

- 4 -

- Counter-solvents which may optionally be added to facilitate crystallisation are liquids which, if added, decrease the solubility of a tertiary amine salts of formula I. Suitable counter-solvents are aliphatic, alicyclic or aromatic hydrocarbons such as (C<sub>5-18</sub>)alkanes, (C<sub>5-10</sub>)cycloalkanes or benzene that may be unsubstituted or substituted by (C<sub>1-6</sub>)alkyl, e.g. 5 toluene, xylene, mesitylene or carboxylic acid esters such as acetic acid-(C<sub>1-4</sub>)-alkyl esters, e.g. n-butylacetate or ethylacetate.

The starting 2-(2-aminothiazol-4-yl)-2-(acyloxyimino)-acetic acid compounds, e.g. in the form of hydrates may be produced by known methods.

10

In another aspect the present invention relates to a process for the production of cefdinir comprising the steps

- a. preparing a tertiary amine salt of formula I in crystalline form, preferably in an anhydrous form, as described above,
- 15 b. reacting the crystalline amine salt obtained from step a. with an activating agent to obtain a 2-(2-aminothiazole-4-yl)-2-acyloxyimino acetic acid compound in an activated form,
- c. reacting the activated 2-(2-aminothiazole-4-yl)-2-acyloxyimino acetic acid compound obtained from step b. with a 7-amino-3-vinyl-3-cephem-4-carboxylic acid compound to obtain a 7-[2-(2-aminothiazole-4-yl)-2-(acyloxyimino)-acetylamo]3-vinyl-3-cephem-4-carboxylic acid compound, and
- 20 d. splitting off the acyl-group at the imino group from a compound as obtained in step c. to obtain cefdinir.

25

- The preparation of a tertiary amine salt of formula I in step a., e.g. in anhydrous form, may be carried out as described above. Step b. may be carried out in analogy, e.g. according to methods known in the art, e.g. in analogy to a process as described in WO 2004/016623. An activated form includes a mercaptobenzothiazoleester, a mixed acid anhydride, an acid halide such as an acid chloride or other conventional activated forms. Examples of activating agents are bis-(benzothiazol-2-yl)-disulphide/triethylphosphite, bis-(benzothiazol-2-yl)-di-sulphide/triphenylphosphine, phosphorous pentachloride, pivaloyl chloride/triethylamine etc. Step c. may be carried out in analogy, e.g. according to known methods. Step d. may be effected in analogy to, e.g. according to methods known in the art, for instance by hydrolysis or alcoholysis with a strong acid. If step d. is performed by alcoholysis, it is desirous to use water-free strong acids. Suitable strong acids include strong

- 5 -

- organic acids such as trifluoroacetic acid, sulfonic acids such as methanesulfonic acid, benzenesulfonic acid or a toluene sulfonic acid, a sulfamic acid and water-free anorganic acids, e.g. sulphuric acid. Cleavage of the acetyl-group is usually carried out in a solvent which does not adversely affect the reaction. Suitable solvents include alcohols such as  
5 methanol, ethanol, propanols, butanols. The reaction is carried out at temperatures from -20 to 30°C, preferably between -5 and +10°C. Typically an excess of anhydrous acid, e.g. from 1.1 to 5.0 molar equivalents are used.

- In another aspect the present invention relates to a process for the production of an  
10 activated form of 2-(2-aminothiazole-4-yl)-2-acyloxyimino acetic acid compounds comprising the steps of preparing a tertiary crystalline amine salt of formula I, e.g. in an anhydrous form, as defined above and reacting the obtained crystalline tertiary amine salt of formula I with an activating agent in order to obtain a 2-(2-aminothiazole-4-yl)-2-acyloxyimino acetic acid compound in an activated form.  
15 A tertiary amine salt of formula I in crystalline form, preferably in an anhydrous form, e.g. prepared by a process as set out above, is useful for the production of an activated form of 2-(2-aminothiazole-4-yl)-2-acylimino acetic acid compounds. An activated form of 2-(2-aminothiazole-4-yl)-2-acylimino acetic acid compounds includes for example an acid halide such as an acid chloride, a mixed acid anhydride and a mercaptobenzothiazolyl ester or  
20 other conventional activated forms resulting from reactions with activating agents such as those listed above.

Therefore, the present invention relates in another aspect to the use of a tertiary amine salt of formula I in crystalline form, e.g. in an anhydrous form, in the preparation of an activated form of 2-(2-aminothiazole-4-yl)-2-acyloxyimino acetic acid compounds.

- 25 A tertiary amine salt of formula I in crystalline form, preferably in an anhydrous form, e.g. prepared by a process as set out above, is useful as an intermediate in the production of cefdinir.  
Therefore, the present invention relates in a further aspect to the use of a tertiary amine salt  
30 of formula I in crystalline form, e.g. in an anhydrous form, in the production of cefdinir.

The following Examples will indicate the different aspects of the present invention and are in no way intended to limit the scope of the present invention. All temperatures are given in °C.

- 35 Abbreviations:  
MeOH: Methanol

- 6 -

HMDS: Hexamethyldisilazane  
TMSI: Trimethyliodsilane  
EtOH: Ethanol  
TsOH: Toluene sulfonic acid  
5 DMAc: Dimethylacetamide

- 7 -

**Example 1**

**(6R,7R)-7-[(2Z)-(2-Amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (Cefdinir)**

- A solution of 21.1 g of 7-[2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)acetamido]-3-vinyl-cephem-4-carboxylic acid in the form of a salt with *ortho*-phosphoric acid in 80 ml of MeOH is mixed at 0° with 3.9 ml of concentrated H<sub>2</sub>SO<sub>4</sub>, the mixture obtained is stirred at ≤10° and added dropwise to a solution of 17.5g NaHCO<sub>3</sub> in 600ml of water. The pH value of the mixture obtained is adjusted to pH 5.3, 1.8 g of activated carbon are added, the mixture is stirred, and the activated carbon is filtered off and washed with H<sub>2</sub>O. The filtrate obtained is heated to 25° to 30° and the pH value is adjusted to pH 3 with 2n H<sub>2</sub>SO<sub>4</sub>. (6R,7R)-7-[(2Z)-(2-Amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid crystallises, is filtered off, washed and dried. Weighed product: 12.08 g.

15   **Example 2**

**Tri-(n-butyl)ammonium (syn-2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)-acetate)**

- 25.0g *syn*-2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)-acetic acid dihydrate (water content: 14.5%) are suspended in 100 ml of acetone at ambient temperature and 24.4ml of tri-(n-butyl)amine are added. The material dissolves and immediately begins to crystallize again. The mixture is cooled to -10°C and stirred at this temperature for 30 minutes. The crystalline material is filtered, washed with a small portion of cold acetone and dried in vacuum.

Weighed product: 32.7g

25   H<sub>2</sub>O: 0.1%

<sup>1</sup>H-nmr(CDCl<sub>3</sub>) δ 0.87(t,9H,J=7.4Hz), 1.29(m,6H), 1.58(m,6H), 2.08(s,3H), 2.89(m,6H), 6.78(s,1H), 7.55(br s,2H)


IR(golden gate): 3431, 3109, 2959, 2873, 1750, 1608, 1375, 1227 cm<sup>-1</sup>

mp: 105 °C (decomposition)

30   X-ray diffraction pattern see figure 1

**Figure 1:** X-ray diffraction pattern of *tri-(n-butyl)ammonium (syn-2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)-acetate)* prepared according to Example 2;

Analytical XRD equipment: Powder X-ray diffractometer AXS-BRUKER D-8; Cu-target ( wavelength CuK $\alpha$ 1,2 : =.15406 nm), scintillation counter, parallel beam optics, theta/theta coupled, 9 position sampler changer; operating conditions: 40kV, 40mA,continuous scan 2-40° theta/2Theta; step size 0.01 steps per second, counting time 2 seconds, room conditions; sample preparation: standard sample holders



**Example 3****Tri(n-butyl)ammonium (syn-2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)-acetate)**

- 5.0g *syn*-2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)-acetic acid monohydrate (water content: 8.0%) is suspended in 20 ml of acetone at ambient temperature and 5.2 ml of tri-(n-butyl)amine are added. The material partly dissolves and immediately begins to crystallize again. The mixture is cooled to -10°C and stirred at this temperature for 60 minutes. The crystalline material is filtered, washed with a small portion of cold acetone and dried in vacuum.
- 10 Weighed product: 7.2g  
H<sub>2</sub>O: 0.5%  
Other physical and spectroscopic data identical as described in example 2.

**Example 4**

- 15 **Tri-(n-butyl)ammonium (syn-2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)-acetate)**  
5.0g *syn*-2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)-acetic acid dihydrate are dissolved in 20 ml of N,N-dimethylformamide at ambient temperature and 5.8ml tri-(n-butyl)amine is added. The clear solution is cooled to 0°C and white crystals are formed.
- 20 200ml acetone are added and the resulting crystal suspension is cooled to -10°C and stirred at this temperature for 60 minutes. The crystalline material is filtered, washed with a small portion of cold acetone and dried in vacuum.  
Weighed product: 5.7g  
H<sub>2</sub>O: 0.1%  
25 Other physical and spectroscopic data identical as described in example 2.

**Example 5****Triethylammonium (syn-2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)-acetate)**

- 5.0g *syn*-2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)-acetic acid dihydrate are dissolved in 20 ml of N,N-dimethylformamide at ambient temperature and 3.4ml of triethylamine are added. The material begins to crystallize and 200ml acetone are added. The mixture is cooled to 0°C and stirred at this temperature for 30 minutes. The crystalline material is filtered, washed with a small portion of cold acetone and dried in vacuum.  
Weighed product: 5.7g  
35 H<sub>2</sub>O: 0.3%

<sup>1</sup>H-nmr(CD<sub>3</sub>OD) δ 1.30(t,9H,J=7.4Hz), 2.19(s,3H), 3.21(q,6H,J=7.4Hz), 7.08(s,1H)

IR(golden gate): 3302, 3096, 2987, 1756, 1613, 1536, 1384, 1356, 1206 cm<sup>-1</sup>

mp: 104 °C (decomposition)

5   **Example 6**

*Diisopropylethylammonium (syn-2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)-acetate)*

- 5.0g *syn*-2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)-acetic acid dihydrate are dissolved in 20 ml of N,N-dimethylformamide at ambient temperature and 4.2ml of 10 diisopropylethylamine are added. The material begins to crystallize and 200ml acetone are added. The mixture is stirred at this temperature for 60 minutes. The crystalline material is filtered, washed with a small portion of acetone and dried in vacuum.

Weighed product: 6.3g

H<sub>2</sub>O: 0.2%

- 15   <sup>1</sup>H-nmr(CD<sub>3</sub>OD) δ 1.35(m,15H), 2.19(s,3H), 3.20(q,2H,J=7.3Hz), 3.70(m,2H), 7.06(s,1H)  
IR(golden gate): 3244, 3111, 2986, 1752, 1613, 1541, 1387, 1363, 1218 cm<sup>-1</sup>  
mp: 110 °C (decomposition)

**Example 7**

- 20   *Tri(n-octyl)ammonium (syn-2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)-acetate)*  
5.0g *syn*-2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)-acetic acid dihydrate are suspended in 100 ml of acetone at ambient temperature and 9.7ml of tri-(n-octyl)amine is added. The material dissolves and the mixture is cooled to -20°C for crystallisation and 25 stirred at this temperature. The crystalline material is filtered, washed with a small portion of cold acetone and dried in vacuum.

Weighed product: 8.2g

H<sub>2</sub>O: 0.2%

- 1' H-nmr(CDCl<sub>3</sub>) δ 0.82(t,9H,J=6.8Hz), 1.22(m,30H), 1.61(m,6H), 2.09(s,3H), 2.89(m,6H),  
30 6.79(s,1H), 7.55(br s,2H)  
IR(golden gate): 3427, 3100, 2924, 2855, 1757, 1612, 1365, 1216 cm<sup>-1</sup>  
mp: 90 °C (decomposition)

**Example 8****Syn-2-(2-Aminothiazol-4-yl)-2-(methylcarbonyloxyimino)-acetic acid-mercaptobenzothiazoleester**

- 12.7 g crystalline anhydrous tri(n-butyl)ammonium (*syn*-2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)-acetate) (water content 0.1% by weight) are dissolved at room temperature in 70 ml of methylene chloride and then cooled to 0°C. The solution is mixed with 13.2g of bis-(benzothiazol-2-yl)-disulphide and stirred thoroughly for 5 minutes. In a period of 20 minutes, 7.3ml of triethylphosphite are dispensed in and the solution is stirred vigorously for ½ hours at 0°C, subsequently cooled to -15°C and stirred for a further 1½ hours. The yellowish crystalline product is filtered, washed three times, each time with 20 ml cold methylene chloride, and dried over night in a vacuum at 30°C.

Weighed product: 11.2g

<sup>1</sup>H-nmr(DMSO-d<sub>6</sub>) δ2.22(s, 3H), 7.36(s, 1H), 7.48(br s, 2H), 7.59(m, 2H), 8.09(m, 1H), 8.22(m, 1H)

15

**Example 9****7-[2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)acetamido]-3-vinyl-cephem-4-carboxylic acid,para-toluenesulfonate**

- 15.0g 7-amino-3-vinyl-3-cephem-4-carboxylic acid are suspended in 150ml dichloromethane and the mixture heated to boiling. 13.6ml HMDS and 10μl TMSI are added and the mixture heated for 2h under reflux conditions and passing a nitrogen stream through the solution. The clear solution is cooled to 30°C and mixed with 30ml DMAc. 27.6g *syn*-2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino) acetic acid -mercaptobenzthiazolester is added in 1 portion and stirred for 3h at 30°C. The reaction mixture is added dropwise to a solution of 16.40g TsOH.hydrate in a mixture of 31.5ml EtOH and 7.2ml water. The product crystallizes out. The suspension is diluted with 360ml methylene chloride and stirred for 60min at 0°C. The crystalline product is filtered off and washed three times, each time with 75ml cold methylene chloride, and dried under vacuum at 30°C.

30 Yield: 39.32g

<sup>1</sup>H-nmr(DMSO-d<sub>6</sub>) δ 2.21(s,3H), 2.28(s,3H), 3.61&3.89(ABq, 2H,J=17.7Hz), 5.25(d,1H,J=4.8Hz), 5.32(d,1H,J=11.4Hz), 5.61(d,1H,J=17.5Hz), 5.84(dd,1H,J=4.8&7.9Hz), 6.92(dd,1H,J=11.1&17.4Hz), 7.12&7.48(AA'BB'm,4H), 7.22(s,1H), 10.04(d,1H,J=7.9Hz)

Toluenesulfonic acid: 26.0%

35 Mp: 145°C (decomposition).


**Example 10****7-[2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)acetamido]-3-vinyl-cephem-4-carboxylic acid phosphate**

- 21.43g 7-amino-3-vinyl-3*I*-cephem-4-carboxylic acid are suspended in 214ml  
5 dichloromethane, mixed with 15.68ml HMDS and 29 $\mu$ l TMSI at RT and heated for 2h under reflux conditions and passing a nitrogen stream through the solution. The mixture is cooled to 30°C and 42.9ml DMAc and 39.4g *syn*-2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)-acetic acid-mercaptopenzthiazolester are added. The mixture is stirred for 2.0 h at 30°C, cooled to 0°C and the reaction mixture added dropwise at 0°C to a  
10 solution of 7.0ml 85% phosphoric acid in 53.6ml MeOH and 11.2ml water, on which a thick crystalline suspension is formed. The suspension is diluted with 257ml methylenechloride, stirred for 1h at 0°C and filtered. The filter cake is washed once with a mixture of 90ml methylenechloride and 17ml MeOH, and then twice more, each time with 107ml methylenechloride, followed by vacuum drying at ambient room temperature.  
15  
Yield: 42.60g  
<sup>1</sup>H-nmr(DMSO-d<sub>6</sub>)  $\delta$  2.17(s,3H), 3.59&3.88(ABq, 2H,J=17.6Hz), 5.23(d,1H,J=4.8Hz),  
5.31(d,1H,J=11.4Hz), 5.60(d,1H,J=17.5Hz), 5.82(dd,1H,J=4.8&8.0Hz),  
6.90(dd,1H,J=11.2&17.6Hz), 7.08(s,1H), 9.91(d,1H,J=8.0Hz)  
20 H<sub>3</sub>PO<sub>4</sub>: 16.9%  
Mp: 170°C (decomposition)

**Claims**


1. A tertiary amine salt of 2-(2-aminothiazole-4-yl)-2-(acyloxyimino)acetic acid in crystalline form of formula

5



wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> independently represents unsubstituted or substituted alkyl, cyclo-alkyl or aryl, and R<sub>4</sub> denotes acyl.

- 10 2. The compound according to claim 1 wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> each denote n-octyl, n-butyl, phenyl or ethyl, or wherein R<sub>1</sub> and R<sub>2</sub> each denote iso-propyl and R<sub>3</sub> denotes ethyl.
- 15 3. The compound according to claim 1 or claim 2 in an anhydrous form.
4. The compound according to claim 3 with a water content of below 1% (w/w).
5. The compound according to any one of claims 1 to 4 wherein R<sub>4</sub> is acetyl.
- 20 6. A process for the preparation of a crystalline tertiary amine salt of formula I as defined in claim 1 comprising the step of bringing an amine of formula



- 25 where R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are as defined in claim 1, into contact with a suspension or solution of a 2-(2-aminothiazole-4-yl)-2-(acyloxyimino)acetic acid compound in a solvent to obtain an amine salt of formula I in crystalline form.

- 14 -

7. The process according to claim 6 wherein a 2-(2-aminothiazole-4-yl)-2-(acylimino)acetic acid compound in the form of a hydrate is dissolved or suspended before it is contacted with the amine of formula II.
- 5    8. A process for the production of cefdinir comprising the steps
  - a. preparing a tertiary amine salt of formula I in crystalline form as defined in any one of claims 1 to 5,
  - b. reacting the crystalline amine salt obtained from step a. with an activating agent to obtain 2-(2-aminothiazole-4-yl)-2-acylxyimino acetic acid in an activated form,
  - c. reacting the activated 2-(2-aminothiazole-4-yl)-2-acyloxyimino acetic acid obtained from step b. with 7-amino-3-vinyl-3-cephem-4-carboxylic acid to obtain a 7-[2-(2-aminothiazole-4-yl)-2-(acyloxyimino)-acetylamino]-3-vinyl-3-cephem-4-carboxylic acid, and
  - 10    d. splitting off the acyl-group at the imino group from a compound as obtained in step c. to obtain cefdinir.
- 15    9. The process according to claim 8 wherein the activated form of a 2-(2-aminothiazole-4-yl)-2-acyloxyimino acetic acid compound is a mercaptobenzothiazolylester, an acid halogenide or a mixed acid anhydride.
- 20    10. A process for the production of an activated form of a 2-(2-aminothiazole-4-yl)-2-acyloxyimino acetic acid compound wherein a tertiary amine salt of formula I as defined in any one of claims 1 to 5 is prepared and then reacted with an activating agent.
- 25    11. Use of a tertiary amine salt of formula I in crystalline form as defined in any one of claims 1 to 5 in the production of an activated form of a 2-(2-aminothiazole-4-yl)-2-acylimino acetic acid compound.
- 30    12. Use of a tertiary amine salt of formula I in crystalline form as defined in any one of claims 1 to 5 in the production of cefdinir.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2005/007958

**A. CLASSIFICATION OF SUBJECT MATTER**  
C07D277/20 A61K31/425

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2004/016623 A (SANDOZ GMBH; KREMMINGER, PETER; WOLF, SIEGFRIED; LUDESCHER, JOHANNES) 26 February 2004 (2004-02-26) page 8, line 16 – page 8, line 19 examples 2,3 claim 9 the whole document	1-12
Y	EP 0 185 220 A (F. HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT) 25 June 1986 (1986-06-25) Formelschema I (Verbindungen der Formel VIII), Column 4, lines 19 and 20 Example (Beispiel), Step c), column 7, lines 7 and 8	1-12 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the International filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the International search

7 December 2005

Date of mailing of the International search report

15/12/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Deutsch, W

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2005/007958

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 1 340 751 A (FUJISAWA PHARMACEUTICAL CO., LTD) 3 September 2003 (2003-09-03) the whole document examples 1,2	1-12
A	EP 0 531 981 A (BRISTOL-MYERS SQUIBB COMPANY) 17 March 1993 (1993-03-17) the whole document page 5, formula III	1-12
A	ES 2 013 828 A6 (FUJISAWA PHARMACEUTICAL CO., LTD) 1 June 1990 (1990-06-01) cited in the application the whole document	1-12

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP2005/007958

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 2004016623	A 26-02-2004	AU EP	2003255424 A1 1554289 A1	03-03-2004 20-07-2005
EP 0185220	A 25-06-1986	JP	61145187 A	02-07-1986
EP 1340751	A 03-09-2003	AU CA CN WO US	2255302 A 2430840 A1 1479730 A 0246175 A1 2004034233 A1	18-06-2002 13-06-2002 03-03-2004 13-06-2002 19-02-2004
EP 0531981	A 17-03-1993	AT AU AU BG CA CN CN CZ CZ DE DE DK EG ES FI FI HU IL JP JP KR MX NO NZ OA PH PL PT RO SK SK RU ZA	209209 T 655838 B2 2284492 A 61189 B1 2077836 A1 1070398 A 1158333 A 9202780 A3 9600719 A3 69232216 D1 69232216 T2 531981 T3 20184 A 2165351 T3 924031 A 20011921 A 62901 A2 103109 A 3434840 B2 5194532 A 178280 B1 9205147 A1 923495 A 244295 A 9764 A 31206 A 295873 A1 531981 T 109651 B1 33698 A3 278092 A3 2042681 C1 9206866 A	15-12-2001 12-01-1995 11-03-1993 28-02-1997 11-03-1993 31-03-1993 03-09-1997 17-03-1993 11-06-1997 03-01-2002 27-06-2002 21-05-2002 30-09-1997 16-03-2002 11-03-1993 01-10-2001 28-06-1993 13-07-1997 11-08-2003 03-08-1993 20-03-1999 01-03-1993 11-03-1993 28-08-1995 30-11-1993 05-05-1998 04-05-1993 31-05-2002 28-04-1995 12-09-2000 12-09-2000 27-08-1995 09-03-1993
ES 2013828	A6 01-06-1990	CA JP JP KR	1340604 C 2000790 A 2600878 B2 140887 B1	22-06-1999 05-01-1990 16-04-1997 01-06-1998